Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R. Zaja F, et al. Among authors: regazzi m. Haematologica. 2008 Jun;93(6):930-3. doi: 10.3324/haematol.12206. Epub 2008 Apr 9. Haematologica. 2008. PMID: 18403395 Free article.
Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.
Montagna M, Montillo M, Avanzini MA, Tinelli C, Tedeschi A, Visai L, Ricci F, Vismara E, Morra E, Regazzi M. Montagna M, et al. Among authors: regazzi m. Haematologica. 2011 Jun;96(6):932-6. doi: 10.3324/haematol.2010.033159. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330330 Free PMC article. Clinical Trial.
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.
Golay J, Semenzato G, Rambaldi A, Foà R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, Regazzi M. Golay J, et al. Among authors: regazzi m. MAbs. 2013 Nov-Dec;5(6):826-37. doi: 10.4161/mabs.26008. Epub 2013 Aug 8. MAbs. 2013. PMID: 23933992 Free PMC article. Review.
Rituximab in children with resistant idiopathic nephrotic syndrome.
Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM. Magnasco A, et al. Among authors: regazzi m. J Am Soc Nephrol. 2012 Jun;23(6):1117-24. doi: 10.1681/ASN.2011080775. Epub 2012 May 10. J Am Soc Nephrol. 2012. PMID: 22581994 Free PMC article. Clinical Trial.
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E. Montillo M, et al. Among authors: regazzi m. J Clin Oncol. 2006 May 20;24(15):2337-42. doi: 10.1200/JCO.2005.04.6037. Epub 2006 Apr 17. J Clin Oncol. 2006. PMID: 16618945 Clinical Trial.
179 results